Type 2 Diabetes clinical trial intelligence

A Comparison of the Effects of Different Periodization-Based Strength Training Programs in Individuals With Type 2 Diabetes Mellitus

A Comparison of the Effects of Different Periodization-Based Strength Training Programs in Individuals With Type 2 Diabetes Mellitus is a NA clinical asset sponsored by Baskent University in Type 2 Diabetes. SEO and diligence focus: Non-linear Periodization-Based Strength Training, Linear Periodization-Based Strength Training, Usual Care, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Type 2 Diabetes

Artificial Saliva in Diabetes Type II: a Randomized Registry Cross Over Study

Artificial Saliva in Diabetes Type II: a Randomized Registry Cross Over Study is a NA clinical asset sponsored by Certmedica International GmbH in Xerostomia Due to Hyposecretion of Salivary Gland, Diabetes Mellitus, Type 2. SEO and diligence focus: artificial saliva spray (AS), maritime throat spray (TT), endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Diabetes Mellitus, Type 2

A Randomized Trial Comparing Insulin Lispro Protamine Suspension With Insulin Glargine in Subjects With Type 2 Diabetes on Oral Antihyperglycemic Medications and Exenatide

A Randomized Trial Comparing Insulin Lispro Protamine Suspension With Insulin Glargine in Subjects With Type 2 Diabetes on Oral Antihyperglycemic Medications and Exenatide is a PHASE3 clinical asset sponsored by Eli Lilly and Company in Diabetes Mellitus, Type 2. SEO and diligence focus: Insulin Lispro Protamine Suspension, Insulin Glargine, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Diabetes Mellitus, Type 2

Liraglutide or Insulin in Real Life Usage in Patients With Diabetes Mellitus Type 2

Liraglutide or Insulin in Real Life Usage in Patients With Diabetes Mellitus Type 2 is a registry-stage clinical asset sponsored by Novo Nordisk A/S in Diabetes, Diabetes Mellitus, Type 2. SEO and diligence focus: liraglutide, insulin, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Diabetes Mellitus, Type 2

A Randomized Study to Investigate the Effect of Low-calorie Diets With Different Macronutrient Composition and Macronutrient Distribution in Shift Workers With Prediabetes or Type 2 Diabetes and Overweight or Obesity.

A Randomized Study to Investigate the Effect of Low-calorie Diets With Different Macronutrient Composition and Macronutrient Distribution in Shift Workers With Prediabetes or Type 2 Diabetes and Overweight or Obesity. is a NA clinical asset sponsored by Universidad de Zaragoza in Type 2 Diabetes, Overweight or Obesity, PreDiabetes. SEO and diligence focus: Diet, Diet, Diet, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Type 2 Diabetes

Glycemic Control and Treatment Satisfaction Using Finesse Versus Pen for Initiating Bolus Insulin Dosing in Type 2 Diabetes Mellitus Patients Not Achieving Glycemic Targets on Basal Insulin With/Without Anti-Hyperglycemic Agents

Glycemic Control and Treatment Satisfaction Using Finesse Versus Pen for Initiating Bolus Insulin Dosing in Type 2 Diabetes Mellitus Patients Not Achieving Glycemic Targets on Basal Insulin With/Without Anti-Hyperglycemic Agents is a NA clinical asset sponsored by Calibra Medical, Inc. in Diabetes Mellitus, Type 2. SEO and diligence focus: Bolus Insulin Patch (Calibra Finesse), Insulin Pen (Novo-Nordisk FlexPen®), endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Diabetes Mellitus, Type 2

A Phase IIA , Multi-center, Randomized, Double-blind, Placebo and Positive Drug Parallel Control Study of TQ-F3083 Capsules With Different Doses in Subjects With Type 2 Diabetes Mellitus

A Phase IIA , Multi-center, Randomized, Double-blind, Placebo and Positive Drug Parallel Control Study of TQ-F3083 Capsules With Different Doses in Subjects With Type 2 Diabetes Mellitus is a PHASE2 clinical asset sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. in Type 2 Diabetes Mellitus. SEO and diligence focus: TQ-F3083 capsule 10 mg, TQ-F3083 capsule 20 mg, TQ-F3083 blank analog capsule, TQ-F3083 blank analog capsule, Linagliptin blank analog tablet, Linagliptin tablet, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Type 2 Diabetes Mellitus

A Randomised, Open, Placebo Controlled, Two-way Crossover Phase I Study in Type 2 Diabetes Mellitus Patients Treated With Metformin to Evaluate the Effect of Gemfibrozil on the Pharmacokinetics and Pharmacodynamics of a Single Dose of AZD1656

A Randomised, Open, Placebo Controlled, Two-way Crossover Phase I Study in Type 2 Diabetes Mellitus Patients Treated With Metformin to Evaluate the Effect of Gemfibrozil on the Pharmacokinetics and Pharmacodynamics of a Single Dose of AZD1656 is a PHASE1 clinical asset sponsored by AstraZeneca in Type 2 Diabetes Mellitus. SEO and diligence focus: AZD1656, Gemfibrozil, Placebo, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Type 2 Diabetes Mellitus

Development of a Group Emotion-Focused Behavioral Intervention for Diabetes Distress and Glycemic Management in Patients With T2D.

Development of a Group Emotion-Focused Behavioral Intervention for Diabetes Distress and Glycemic Management in Patients With T2D. is a NA clinical asset sponsored by Ohio State University in T2DM (Type 2 Diabetes Mellitus). SEO and diligence focus: Group Emotion Focused Behavioral Intervention (G-EFBI), Group - With Every Heartbeat is Life (G-WEHL), endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: T2DM (Type 2 Diabetes Mellitus)

Fully Decentralised Clinical Study Exploring Remote Collection of Glycaemic and Behaviometric Data Among Participants With Type 2 Diabetes Mellitus on Different Treatment Regimens

Fully Decentralised Clinical Study Exploring Remote Collection of Glycaemic and Behaviometric Data Among Participants With Type 2 Diabetes Mellitus on Different Treatment Regimens is a registry-stage clinical asset sponsored by Novo Nordisk A/S in Diabetes Mellitus, Type 2. SEO and diligence focus: Oral antidiabetetic drugs, Basal insulin, Glucagon-like peptide-1 (GLP-1), endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Diabetes Mellitus, Type 2

A Long-term, Randomized, Open-labeled, Parallel-group Trial to Compare the Effects of Liraglutide and Sulphonylurea (Glimepiride) Both in Combination With Metformin on Clinical, Endothelial and Image Markers of Cardiovascular Risk in Patients With Type 2 Diabetes

A Long-term, Randomized, Open-labeled, Parallel-group Trial to Compare the Effects of Liraglutide and Sulphonylurea (Glimepiride) Both in Combination With Metformin on Clinical, Endothelial and Image Markers of Cardiovascular Risk in Patients With Type 2 Diabetes is a PHASE4 clinical asset sponsored by Fundación Fernández-Cruz in Type 2 Diabetes. SEO and diligence focus: Liraglutide + metformin, Glimepiride + metformin, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Type 2 Diabetes

Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus

Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus is a PHASE3 clinical asset sponsored by Novo Nordisk A/S in Diabetes, Diabetes Mellitus, Type 2. SEO and diligence focus: semaglutide, liraglutide, placebo, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Diabetes Mellitus, Type 2

A Multiple Dose Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1403 in Participants With Type 2 Diabetes Mellitus

A Multiple Dose Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1403 in Participants With Type 2 Diabetes Mellitus is a PHASE1 clinical asset sponsored by Merck Sharp & Dohme LLC in Diabetes Mellitus, Type 2. SEO and diligence focus: MK-1403 + additive coformulation, Placebo + additive coformulation, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Diabetes Mellitus, Type 2

The Use of Acarbose to Treat Postprandial Hypotension in Older Adults With Type 2 Diabetes

The Use of Acarbose to Treat Postprandial Hypotension in Older Adults With Type 2 Diabetes is a PHASE2 clinical asset sponsored by University of British Columbia in Type 2 Diabetes, Postprandial Hypotension. SEO and diligence focus: Acarbose, Placebo, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Type 2 Diabetes

Efficacy and Safety of Tirzepatide Once Weekly in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-2)

Efficacy and Safety of Tirzepatide Once Weekly in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-2) is a PHASE3 clinical asset sponsored by Eli Lilly and Company in Type 2 Diabetes, Overweight, Obesity. SEO and diligence focus: Tirzepatide, Placebo, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Type 2 Diabetes

A 26-week Open Label, Randomised, 2-armed, Parallel Group, Multi-centre Trial Investigating Efficacy and Safety of Insulin Detemir Versus Insulin Neutral Protamine Hagedorn in Combination With the Maximum Tolerated Dose of Metformin and Diet/Exercise on Glycaemic Control in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on the Maximum Tolerated Dose of Metformin ± Other Oral Antidiabetic Drug(s) ± Basal Insulin

A 26-week Open Label, Randomised, 2-armed, Parallel Group, Multi-centre Trial Investigating Efficacy and Safety of Insulin Detemir Versus Insulin Neutral Protamine Hagedorn in Combination With the Maximum Tolerated Dose of Metformin and Diet/Exercise on Glycaemic Control in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on the Maximum Tolerated Dose of Metformin ± Other Oral Antidiabetic Drug(s) ± Basal Insulin is a PHASE3 clinical asset sponsored by Novo Nordisk A/S in Diabetes, Diabetes Mellitus, Type 2. SEO and diligence focus: Insulin detemir, Insulin NPH, Diet/exercise, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

A Prospective, Multicenter, Phase -IV Study to Assess the Safety of Fixed Dose Combination of Dapagliflozin and Saxagliptin in Indian Type 2 Diabetes Mellitus (T2D) Patients

A Prospective, Multicenter, Phase -IV Study to Assess the Safety of Fixed Dose Combination of Dapagliflozin and Saxagliptin in Indian Type 2 Diabetes Mellitus (T2D) Patients is a PHASE4 clinical asset sponsored by AstraZeneca in Type 2 Diabetes Mellitus. SEO and diligence focus: dapagliflozin and saxagliptin, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Type 2 Diabetes Mellitus

A Bioequivalence Study of Fixed-dose Combination Tablet of 5 Milligrams Saxagliptin/10 Milligrams Dapagliflozin Relative to Their Respective Individual Components Coadministered to Healthy Subjects in the Fasted State

A Bioequivalence Study of Fixed-dose Combination Tablet of 5 Milligrams Saxagliptin/10 Milligrams Dapagliflozin Relative to Their Respective Individual Components Coadministered to Healthy Subjects in the Fasted State is a PHASE1 clinical asset sponsored by AstraZeneca in Type 2 Diabetes Mellitus. SEO and diligence focus: Saxagliptin, Dapagliflozin, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Type 2 Diabetes Mellitus

Behavioral Family Systems Therapy for Teens With Type 2 Diabetes: A Pilot

Behavioral Family Systems Therapy for Teens With Type 2 Diabetes: A Pilot is a NA clinical asset sponsored by Nemours Children's Clinic in Diabetes Mellitus, Type 2, Childhood Obesity. SEO and diligence focus: BFST for Teens with Type 2 Diabetes, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Diabetes Mellitus, Type 2

NYSCF Scientific Discovery Biobank

NYSCF Scientific Discovery Biobank is a registry-stage clinical asset sponsored by New York Stem Cell Foundation Research Institute in ALS, Amyotrophic Lateral Sclerosis, Alzheimer Disease, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Batten Disease, Corticobasal Degeneration, Dementia, Frontotemporal Dementia, Huntington Disease, Lewy Body Disease, Multiple Sclerosis, Multiple System Atrophy, Parkinson Disease, Parkinson's Disease and Parkinsonism, Progressive Supranuclear Palsy, INAD, Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Macular Degeneration, Ovarian Cancer, Cervical Cancer, Uterine Cancer, Vaginal Cancer, Vulvar Cancer, PTSD, Post Traumatic Stress Disorder. SEO and diligence focus: Biological Sample Collection, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Diabetes Mellitus, Type 2

A Phase 2 Study of Once-Weekly LY3298176 Compared With Placebo and Dulaglutide in Patients With Type 2 Diabetes Mellitus

Eli Lilly's tirzepatide is positioned to compete in the growing Type 2 diabetes market, which is projected to reach $70 billion by 2025. The drug's once-weekly administration and dual receptor action may provide a competitive edge over existing therapies such as dulaglutide. Successful outcomes from this trial could enhance Eli Lilly's portfolio and market share, particularly against other GLP-1 receptor agonists. The trial's completion and subsequent data readouts will be critical for investor confidence and potential partnerships or licensing opportunities.

Matched by conditions: Type 2 Diabetes Mellitus

MultI-eLectrode EndovaScular denervaTiOn in patieNts With Type 2 Diabetes mEllitus (MILESTONE) Study

The MILESTONE study, sponsored by Zhongda Hospital, aims to evaluate the efficacy of multi-electrode catheter-based endovascular denervation in improving glucose metabolism and insulin sensitivity in patients with Type 2 Diabetes Mellitus (T2DM). Given the increasing prevalence of T2DM globally, successful outcomes from this trial could position the intervention as a novel therapeutic option in a market characterized by a high demand for effective diabetes management solutions. The competitive landscape includes traditional pharmacological treatments and emerging technologies targeting metabolic pathways. Diligence should focus on the trial's recruitment progress, safety profile, and potential regulatory pathways, especially considering the device nature of the intervention.

Matched by conditions: Type 2 Diabetes Mellitus

Randomisation to Endoluminal Intestinal Liner Alone Versus With Incretin Analogue in SustainEd Diabesity (REVISE-Diabesity)

The REVISE-Diabesity trial investigates the efficacy of the Endobarrier device in conjunction with Liraglutide for treating obesity and type 2 diabetes in patients unresponsive to conventional therapies. Given the rising prevalence of obesity and T2DM, this study addresses a significant unmet medical need, potentially positioning the Endobarrier as a viable non-surgical alternative to bariatric surgery. The outcomes could enhance market competitiveness against existing GLP-1 receptor agonists and other obesity treatments, while also informing future product development strategies. Stakeholders should consider the implications of successful results on market access, reimbursement strategies, and potential partnerships for commercialization.

Matched by conditions: Type 2 Diabetes

Evaluation of the Impact of the FreeStyle Libre 2 Flash Glucose Monitoring System, Compared to the Current Standard of Care (SOC), on Weight Reduction in Subjects With Type 2 Diabetes.

The clinical trial aimed to evaluate the efficacy of the FreeStyle Libre 2 system in promoting weight reduction among individuals with Type 2 Diabetes compared to the current standard of care. The trial was terminated due to slow enrollment and the study being deemed no longer required. This outcome suggests potential challenges in market adoption or interest in the comparative efficacy of glucose monitoring systems for weight management. Abbott Diabetes Care may need to reassess its strategy regarding the FreeStyle Libre 2, particularly in the context of competitive offerings in diabetes management and weight loss solutions. The termination of the trial may also impact investor confidence and future funding opportunities for related research.

Matched by conditions: Diabetes Mellitus, Type 2

Perturbation of Interactome Through Micro-RNA And Methylome Analyses In Diabetes Endophenotypes: the PIRAMIDE Study Design

The PIRAMIDE study, led by Giuditta Benincasa at the University of Campania Luigi Vanvitelli, aims to elucidate the interplay between DNA methylation and microRNA in T2D and its cardiovascular complications. Given the rising prevalence of T2D globally, understanding these molecular interactions could lead to novel prognostic biomarkers and therapeutic targets, enhancing the competitive landscape in diabetes management. The study's findings may provide insights that could be leveraged for developing epigenetic-based interventions or diagnostics, potentially positioning the sponsor favorably in the growing diabetes and cardiovascular disease markets.

Matched by conditions: Type 2 Diabetes Mellitus

Mechanistic Studies in Human Subcutaneous Adipose Tissue

The AMIGROS study, sponsored by Vastra Gotaland Region, aims to elucidate the role of galectin-1 in obesity and type 2 diabetes by comparing obese insulin-sensitive (Ob-IS) and insulin-resistant (Ob-IR) subjects with lean controls. Given the increasing prevalence of obesity and type 2 diabetes globally, understanding the mechanistic pathways involving galectin-1 could lead to novel therapeutic targets. The findings may have significant implications for drug development in metabolic disorders, particularly in identifying biomarkers for early intervention and personalized treatment strategies. The study's observational nature may limit immediate commercial applications but could pave the way for future clinical trials targeting galectin-1 modulation. The competitive landscape includes existing diabetes and obesity therapies, necessitating a robust differentiation strategy based on the mechanistic insights gained from this research.

Matched by conditions: Type 2 Diabetes

Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 Diabetes

The trial evaluates liraglutide, a GLP-1 receptor agonist, against sulphonylurea in combination with metformin for managing Type 2 Diabetes Mellitus (T2DM) during Ramadan fasting. Given the increasing prevalence of diabetes in Muslim populations, particularly in Africa and Asia, successful outcomes could enhance liraglutide's market position against established therapies like sulphonylureas. The results may support expanded indications for liraglutide, potentially increasing its market share in diabetes management. Competitive implications include the need for Novo Nordisk to monitor responses from other diabetes therapies, particularly those targeting fasting-related glycemic control. Diligence should focus on the safety profile and patient adherence during fasting periods, which could influence prescribing patterns.

Matched by conditions: Diabetes Mellitus, Type 2

Exercise and Pioglitazone for HIV-Metabolic Syndromes

The clinical trial investigated the combined effects of pioglitazone, a PPAR-gamma agonist, and structured exercise training on metabolic syndromes in HIV-infected individuals. Given the rising prevalence of metabolic disorders among HIV patients, this study addresses a significant unmet medical need. The findings could enhance pioglitazone's market positioning against other diabetes and metabolic syndrome treatments, particularly in the context of HIV-associated complications. The results may also support the development of combination therapies, potentially leading to new indications for pioglitazone and exercise interventions in this patient population.

Matched by conditions: Type 2 Diabetes

Restoring Insulin Secretion Pediatric Medication Study

The RISE Pediatric Medication Study investigates the efficacy of metformin alone versus a combination of basal insulin glargine followed by metformin in restoring beta-cell function in children aged 10-19 with prediabetes and early type 2 diabetes. Given the rising prevalence of type 2 diabetes in pediatric populations, successful outcomes could position the sponsor favorably in a growing market. The study's completion and results may enhance the competitive landscape for diabetes treatments targeting pediatric patients, particularly against existing therapies like insulin and metformin. Stakeholders should consider potential partnerships or licensing opportunities based on the results, as well as the implications for reimbursement strategies in pediatric diabetes care.

Matched by conditions: Type 2 Diabetes

A Phase IIa, Randomised, Parallel, Double-Blind,Placebo-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of MEDI0382 in Japanese Preobese or Obese Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Diet and Exercise

MEDI0382, developed by AstraZeneca, targets the Japanese market for Type 2 Diabetes Mellitus (T2DM) treatment, particularly among preobese and obese patients with inadequate glycemic control. The competitive landscape includes established GLP-1 receptor agonists and emerging glucagon receptor agonists. The successful outcome of this trial could position AstraZeneca favorably against competitors, especially in a market where diabetes prevalence is rising. Diligence should focus on the safety profile and efficacy data, as these will be critical for regulatory approval and market acceptance.

Matched by conditions: Type 2 Diabetes

The I-KAN Study: Internet Initiation of Insulin for Type 2 Diabetes in Kansas

The I-KAN Study demonstrates the feasibility and safety of an innovative Internet-based education model for insulin management in Type 2 Diabetes patients, particularly in rural areas. Given the increasing prevalence of diabetes and the need for effective management solutions, this model could represent a significant opportunity for healthcare providers and digital health companies. The findings may support further development of telehealth solutions and educational platforms, potentially leading to partnerships with pharmaceutical companies that manufacture insulin products. The study's outcomes could also influence reimbursement policies for digital health interventions, enhancing market access for similar future initiatives.

Matched by conditions: Type 2 Diabetes

Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3457263 Alone and in Combination With GLP-1 RA in Patients With Type 2 Diabetes

LY3457263, developed by Eli Lilly, is positioned to enhance the treatment landscape for Type 2 Diabetes (T2D) through its dual mechanism of action when combined with GLP-1 receptor agonists. The study's completion indicates progress towards potential market entry, with a focus on patients inadequately controlled by existing therapies. Given the competitive landscape, including established GLP-1 RAs like Dulaglutide, the success of LY3457263 could provide Eli Lilly with a differentiated product offering, particularly if safety and efficacy profiles are favorable. The T2D market continues to expand, driven by rising prevalence and increasing treatment options, suggesting significant commercial potential for successful candidates.

Matched by conditions: Diabetes Mellitus, Type 2

Development and Evaluation of a Computer-Based, Self-Management Tool for People Recently Diagnosed With Type 2 Diabetes (Evaluation Phase)

The clinical trial conducted by Queen's University, Belfast, evaluated a computer-based self-management tool aimed at improving diabetes care for individuals recently diagnosed with Type 2 diabetes. The market for diabetes management tools is expanding, driven by increasing prevalence rates and a growing emphasis on patient-centric care. This trial's findings could position the developed tool as a valuable adjunct to traditional diabetes management, potentially leading to partnerships with healthcare providers and technology firms. Competitive implications include the need to assess similar digital health solutions in the market and their efficacy in improving patient outcomes. Diligence considerations should focus on the tool's scalability, integration with existing healthcare systems, and regulatory compliance.

Matched by conditions: Diabetes Mellitus, Type 2

A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Phase 2a Study With an Open-Label Active Group to Assess the Efficacy and Safety of Once-Daily NNC0090-2746 in Type 2 Diabetic Patients Inadequately Controlled With Metformin

NNC0090-2746, developed by Novo Nordisk A/S, is positioned as a novel adjunct therapy for Type 2 Diabetes (T2D) patients inadequately controlled with metformin. The dual action on GIP and GLP-1 receptors may provide a competitive edge in a crowded diabetes market, particularly against established therapies such as GLP-1 receptor agonists (e.g., liraglutide). The trial's completion and results could enhance Novo Nordisk's portfolio, potentially leading to a strong market entry if efficacy and safety are demonstrated. The T2D market is projected to grow significantly, driven by increasing prevalence and demand for innovative therapies, which may present lucrative opportunities for NNC0090-2746.

Matched by conditions: Diabetes Mellitus Type 2

Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only.

Novo Nordisk's oral semaglutide is positioned to compete in the growing diabetes treatment market, particularly targeting patients with Type 2 diabetes who are currently managed with diet and exercise alone. The efficacy and safety profile demonstrated in this trial could enhance Novo Nordisk's portfolio, potentially leading to increased market share against established injectable GLP-1 receptor agonists and other diabetes medications. The global reach of the trial across multiple countries indicates a robust strategy for broad market penetration. Diligence should focus on the competitive landscape, particularly the responses from competitors and the regulatory environment in key markets.

Matched by conditions: Diabetes Mellitus, Type 2

Effect of Liraglutide on Glycaemic Control in Subjects With Type 2 Diabetes

Liraglutide, a GLP-1 receptor agonist developed by Novo Nordisk, is positioned to compete against existing diabetes treatments, particularly sulfonylureas like glibenclamide. The trial conducted in Japan demonstrates liraglutide's potential to improve glycaemic control in Type 2 diabetes patients, which may enhance its marketability in a region with a growing diabetic population. Given the increasing prevalence of Type 2 diabetes globally, successful outcomes could lead to expanded market share and revenue growth for Novo Nordisk. The results may also influence treatment guidelines, potentially leading to a shift in prescribing patterns towards liraglutide over traditional therapies. Diligence should focus on the competitive landscape, particularly the efficacy and safety profiles of other GLP-1 receptor agonists and oral antidiabetic agents.

Matched by conditions: Diabetes Mellitus, Type 2

Insulin Detemir Co-administered With Liraglutide: An Open Label Trial to Assess Insulin Detemir and Liraglutide Pharmacokinetics and Pharmacodynamics Following Liraglutide Therapy in Subjects With Type 2 Diabetes

The trial investigates the pharmacokinetics and pharmacodynamics of insulin detemir when co-administered with liraglutide in patients with type 2 diabetes. Given the increasing prevalence of diabetes and the growing market for combination therapies, successful outcomes could enhance Novo Nordisk's portfolio in diabetes management. The trial's completion in 2009 positions it within a competitive landscape where combination therapies are gaining traction. The results may provide insights into optimizing treatment regimens, potentially leading to improved patient outcomes and increased market share. Additionally, the findings could inform future product development strategies and partnerships.

Matched by conditions: Diabetes Mellitus, Type 2

A Double-blind, Randomized, Parallel, Placebo-controlled 12-week Evaluation of the Safety of Two Doses of TH9507 in Subjects With Stable, Type 2 Diabetes Mellitus

TH9507, a stabilized analogue of growth hormone-releasing factor, is being evaluated for its potential to improve insulin sensitivity in patients with type 2 diabetes. The market for diabetes treatments is substantial, with increasing prevalence driving demand for innovative therapies. Given the competitive landscape, which includes established therapies and emerging agents, successful outcomes from this trial could position Theratechnologies favorably. However, the company must navigate potential regulatory hurdles and market access challenges, particularly in demonstrating clear clinical benefits over existing treatments. Diligence should focus on the safety profile and efficacy data to assess market viability.

Matched by conditions: Type 2 Diabetes

Group Prenatal Care for Women With Diabetes: A Pilot Randomized Control Trial

This pilot randomized control trial, sponsored by Washington University School of Medicine, explores the efficacy of group prenatal care for women with diabetes, specifically targeting self-care activities. The study's outcomes could have significant implications for maternal and neonatal health, particularly in the context of diabetes management during pregnancy. If successful, this approach may lead to broader adoption of group prenatal care models, potentially impacting healthcare delivery and reimbursement strategies in maternal health. The market for diabetes management in pregnancy is substantial, with increasing awareness and demand for innovative care models. Competitively, this trial positions the sponsor as a leader in maternal diabetes care, potentially influencing future guidelines and practices.

Matched by conditions: Type 2 Diabetes

The Effects of Iloprost Infusion on Capillary Recruitment and Whole-body Glucose Uptake in Type 2 Diabetic Patients - a Cross-over Trial.

Iloprost, a stable prostacyclin analogue, is being investigated for its potential to enhance insulin sensitivity and glucose uptake in patients with Type 2 diabetes. Given the increasing prevalence of diabetes and the need for effective treatments, this study could position iloprost as a novel therapeutic option in a competitive market dominated by existing antidiabetic medications. The results may provide insights into iloprost's utility in improving metabolic outcomes, which could attract interest from pharmaceutical companies looking to expand their diabetes portfolios. However, the exclusion of patients with cardiovascular events may limit the generalizability of findings, necessitating further studies to confirm efficacy and safety in broader populations.

Matched by conditions: Diabetes Mellitus, Type 2

Healthy Hearts, Healthy Minds

The 'Healthy Hearts, Healthy Minds' study, sponsored by the University of Washington, targets a critical health issue among American Indians in the Northwest, specifically addressing the intersection of cardiovascular disease (CVD), diabetes, and depression. Given the high prevalence of these conditions in this demographic, the intervention's culturally adapted approach may offer a unique market opportunity for behavioral health solutions tailored to indigenous populations. If the pilot shows efficacy, it could lead to a larger-scale randomized controlled trial (RCT) and potential partnerships with health organizations and governmental bodies focused on minority health disparities. The findings could also inform future product development in behavioral health interventions, particularly those integrating motivational interviewing and cognitive-behavioral therapy (CBT).

Matched by conditions: Diabetes Mellitus, Type 2

Metabolic Effects of Duodenal Jejunal Bypass Liner for the Treatment of Adipose Patients With Type 2 Diabetes Mellitus

The DJBL represents a novel, reversible intervention for managing obesity and T2DM, addressing a significant unmet need in the market for patients who have not succeeded with traditional weight loss methods. Given the rising prevalence of obesity and diabetes globally, this device could capture a substantial share of the weight loss and diabetes management market. The competitive landscape includes traditional bariatric surgeries and pharmacological interventions, but DJBL's non-invasive nature may offer a distinct advantage. Diligence considerations should focus on long-term efficacy, safety data, and potential regulatory pathways for commercialization.

Matched by conditions: Type 2 Diabetes Mellitus

Treatment With Glucagon-Like Peptide-1 Receptor, Exenatide, in Patients With Diabetes and Heart Failure With Normal Left Ventricular Ejection Fraction

The study aimed to evaluate the effects of exenatide, a GLP-1 receptor agonist, on heart failure in patients with type 2 diabetes. Despite the potential market for diabetes medications that also address cardiovascular complications, the trial was terminated due to inadequate recruitment. This indicates challenges in patient enrollment for studies targeting specific comorbidities, which may affect future clinical development strategies. The competitive landscape includes other GLP-1 receptor agonists and heart failure treatments, necessitating a focus on differentiated clinical benefits to capture market share.

Matched by conditions: Diabetes Mellitus, Type 2

Post Marketing Surveillance in Japan on Long Term Drug Use of JARDIANCE® Tablets in Patients With Type 2 Diabetes Mellitus

JARDIANCE (empagliflozin), developed by Boehringer Ingelheim in collaboration with Eli Lilly, is positioned as a leading treatment for Type 2 Diabetes Mellitus (T2DM) in Japan. The completion of this extensive post-marketing surveillance study with over 8,000 participants reinforces its safety and efficacy profile, which is critical for maintaining market share against competitors such as Farxiga (dapagliflozin) and Invokana (canagliflozin). The findings may enhance physician confidence in prescribing JARDIANCE, potentially leading to increased market penetration. Additionally, the study's results could support further regulatory submissions or label expansions, thereby enhancing commercial opportunities.

Matched by conditions: Diabetes Mellitus, Type 2

GLYcemic Control Evaluation by Continuous Glucose Monitor Compared With a1C in Left Ventricular Assist Device-supported Patients (GLYCEM1C-LVAD)

The GLYCEM1C-LVAD study, sponsored by Mayo Clinic, aims to validate the use of hemoglobin A1c as a measure of glycemic control in patients with LVADs, a population that may experience unique challenges in diabetes management. The study leverages the Freestyle Libre 3 Continuous Glucose Monitor (CGM) to provide real-time glucose data, potentially leading to improved patient outcomes through better glycemic control. The findings could enhance the market positioning of CGM devices in specialized patient populations, indicating a growing need for tailored diabetes management solutions. The study's outcomes may influence future guidelines and reimbursement policies, thereby impacting market dynamics and competitive positioning among diabetes management technologies.

Matched by conditions: Type 2 Diabetes Mellitus

A Multi-center, phase3, Open-label Study to Evaluate the Long Term Safety and Efficacy of DWP16001 in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Gemigliptin

Daewoong Pharmaceutical Co. LTD. is advancing DWP16001 through a Phase 3 clinical trial aimed at demonstrating its long-term safety and efficacy in T2DM patients. The market for diabetes therapeutics is substantial, with increasing prevalence driving demand for effective treatments. DWP16001's positioning as an adjunct therapy for patients inadequately controlled on existing medications may provide a competitive edge, particularly in markets with high unmet needs. The trial's outcomes could significantly influence Daewoong's market share and revenue potential in the diabetes sector, contingent upon successful results and subsequent regulatory approvals.

Matched by conditions: T2DM (Type 2 Diabetes Mellitus)

The Effects of Acute Exercise on Glucose Kinetics, Beta-cell Function and the Incretin Effect in Subjects Representative of the Whole Glucose Tolerance Continuum

The study, sponsored by Rigshospitalet, investigates the impact of acute exercise on glucose metabolism across a spectrum of glucose tolerance statuses, including normal, impaired, and type 2 diabetes. Given the rising prevalence of type 2 diabetes and obesity, insights from this trial could inform therapeutic strategies and lifestyle interventions aimed at improving glucose tolerance and metabolic health. The findings may have implications for the development of exercise-based interventions or adjunct therapies that leverage the incretin effect, positioning Rigshospitalet as a potential leader in metabolic health research. The competitive landscape includes other institutions exploring similar metabolic pathways, but this study's unique focus on exercise-induced changes provides a differentiated angle. Diligence should consider potential partnerships with pharmaceutical companies focusing on diabetes management and metabolic disorders.

Effect of Liraglutide or Exenatide Added to a Background Treatment of Metformin, Sulphonylurea or a Combination of Both on Glycaemic Control in Subjects With Type 2 Diabetes

The trial evaluates the efficacy of Liraglutide versus Exenatide in combination with existing oral anti-diabetic treatments for Type 2 diabetes. Given the growing prevalence of diabetes globally, the market for GLP-1 receptor agonists is expanding, with significant competition from other diabetes therapies. The results could reinforce Novo Nordisk's position in the diabetes market, particularly if Liraglutide demonstrates superior efficacy or safety compared to Exenatide. Diligence should focus on the competitive landscape, including pricing strategies and market access considerations, as well as potential regulatory hurdles for new indications.

Matched by conditions: Diabetes Mellitus, Type 2

A Phase 3, Open-Label, Multicenter, Single-Arm Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Dulaglutide 3.0 mg and 4.5 mg in Pediatric Participants 10 to Less Than 18 Years of Age With Type 2 Diabetes Mellitus

Eli Lilly's Phase 3 trial of Dulaglutide in pediatric patients with Type 2 Diabetes Mellitus aims to expand the therapeutic options for this demographic, which is increasingly affected by diabetes. The trial is currently recruiting and is expected to provide critical data on safety, efficacy, and pharmacokinetics. Given the rising prevalence of Type 2 diabetes among children and adolescents, successful outcomes could position Dulaglutide as a leading treatment option in this market segment. The competitive landscape includes other GLP-1 receptor agonists and diabetes therapies, necessitating a strong focus on differentiating factors such as dosing flexibility and safety profiles. Diligence should be exercised regarding regulatory pathways and potential market access challenges, particularly in pediatric populations.

Matched by conditions: Type 2 Diabetes

Investigation of the Pharmacokinetics of Subcutaneously Administered NNC0480-0389 in Participants With Various Degrees of Impaired Renal Function Compared to Participants With Normal Renal Function

Novo Nordisk is advancing NNC0480-0389 as a potential combination therapy for T2D, targeting a significant patient population with renal impairment, which is often underserved in diabetes management. The study's focus on pharmacokinetics in patients with impaired renal function positions the asset favorably in a competitive landscape where renal safety and efficacy are critical. The successful completion of this trial may enhance Novo Nordisk's portfolio in diabetes care, particularly in the context of increasing prevalence of T2D and associated renal complications. The market for diabetes therapies is substantial, with a growing demand for innovative solutions that address the complexities of comorbid conditions.

Matched by conditions: Diabetes Mellitus, Type 2

Effects of Exenatide on Postprandial Hyperlipidemia and Inflammation

The completed clinical trial investigates the effects of exenatide on postprandial hyperlipidemia and inflammation in patients with recently diagnosed type 2 diabetes. Given the increasing prevalence of diabetes and associated cardiovascular risks, successful outcomes could enhance exenatide's market positioning against competitors in the GLP-1 receptor agonist space, such as liraglutide and semaglutide. The findings may support expanded indications for exenatide, potentially increasing its market share and providing a competitive edge in the treatment of postprandial metabolic dysregulation. Stakeholders should consider the implications of these results for future product development and market strategy.

Matched by conditions: Type 2 Diabetes Mellitus

A Randomized, Double-Blind Study With an Open-Label Extension Comparing the Effect of Once-Weekly Dulaglutide With Placebo in Pediatric Patients With Type 2 Diabetes Mellitus (AWARD-PEDS: Assessment of Weekly AdministRation of LY2189265 in Diabetes-PEDiatric Study)

Eli Lilly's dulaglutide, a GLP-1 receptor agonist, is being evaluated for pediatric patients with type 2 diabetes mellitus. The pediatric diabetes market is expanding, driven by rising prevalence rates and increasing awareness of diabetes management in children. If successful, dulaglutide could capture significant market share, competing against other GLP-1 receptor agonists and diabetes therapies. The completion of this trial may enhance Eli Lilly's portfolio and strengthen its position in the diabetes market, particularly in the pediatric segment, which is currently underserved. Diligence should focus on potential regulatory hurdles and the competitive landscape, including emerging therapies targeting similar patient populations.

Matched by conditions: Type 2 Diabetes

Northern Lights Physical Activity Program for Management of Type 2 Diabetes Early in Life: Aboriginal Youth Mentorship Program

The Northern Lights Physical Activity Program, sponsored by the University of Manitoba, targets Type 2 diabetes prevention among Aboriginal youth through a peer-led mentorship model. This program is particularly relevant given the rising prevalence of obesity and diabetes in Indigenous populations. The intervention leverages community engagement and culturally relevant practices, which may enhance its acceptance and effectiveness. The findings could inform future public health initiatives and interventions aimed at similar demographics, potentially leading to partnerships with governmental and non-governmental organizations focused on youth health. The completion of this trial may also attract interest from pharmaceutical companies and health organizations looking to invest in preventative health strategies, particularly those that address social determinants of health.

Matched by conditions: Type 2 Diabetes

A Phase 1b, Randomized, Double-Blind, Active Comparator (Open-Label Exenatide) Controlled Study to Evaluate the Effect of Roflumilast Plus Alogliptin on Postprandial Active GLP-1 Level and 24-hour Glucose Level in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on a Stable Dose of Metformin

AstraZeneca's study evaluates the combination of roflumilast and alogliptin in patients with inadequately controlled Type 2 Diabetes Mellitus (T2DM) on metformin. The market for diabetes therapies is highly competitive, with a growing demand for innovative treatments that enhance glycemic control. The combination therapy could provide a differentiated offering in a crowded market, particularly if it demonstrates superior efficacy or safety compared to existing therapies. Diligence should focus on the potential for regulatory approval and market access strategies, as well as the competitive landscape, including other GLP-1 receptor agonists and DPP-4 inhibitors.

Matched by conditions: Type 2 Diabetes

A Double Blind, Placebo-controlled, Dose-ranging Study to Investigate the Effect on Glycemic Control, Safety, Pharmacokinetics and Pharmacodynamics of GLP-1 in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin.

The clinical trial conducted by Hoffmann-La Roche evaluates a GLP-1 analogue, taspoglutide, in patients with Type 2 Diabetes Mellitus who are on stable metformin therapy. Given the increasing prevalence of diabetes and the growing market for GLP-1 receptor agonists, successful outcomes could position taspoglutide favorably against established competitors such as liraglutide and semaglutide. The trial's completion and the anticipated efficacy and safety data will be critical for strategic positioning in a competitive landscape that includes both established and emerging therapies. The target population of 100-500 individuals indicates a robust dataset that could support regulatory filings and market entry strategies.

Matched by conditions: Diabetes Mellitus Type 2

Heart Rate Variability-Guided Exercise Training in Type 2 Diabetes

The trial, sponsored by the University of Illinois at Chicago, aimed to evaluate a novel approach to exercise training for individuals with type 2 diabetes by utilizing heart rate variability (HRV) to tailor exercise prescriptions. Despite the innovative nature of this intervention, the study was withdrawn due to challenges in participant enrollment and funding cessation. The market for diabetes management solutions is substantial, with increasing demand for personalized treatment options. Companies focusing on exercise-based interventions may find competitive advantages in developing similar HRV-guided programs, especially as the prevalence of type 2 diabetes continues to rise. Diligence should consider the feasibility of recruitment strategies and funding mechanisms for future studies.

Matched by conditions: Type 2 Diabetes

Evaluation the Effect of Mangosteen Supplement as Adjuvant Therapy With Sitagliptin/Metformin in Type 2 Diabetic Iraqi Patients

The trial evaluates the adjunctive use of Mangosteen with established diabetes medications (Sitagliptin and Metformin) in a specific population (Iraqi patients with newly diagnosed T2DM). If successful, this could position Mangosteen as a complementary therapy in the diabetes market, which is experiencing significant growth due to rising prevalence rates. The competitive landscape includes other adjunct therapies and natural supplements, necessitating a thorough market analysis and potential partnerships for commercialization. Diligence should focus on the safety profile and efficacy data to assess market entry viability.

Matched by conditions: Type 2 Diabetes

A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus (DUAL™ V - Basal Insulin Switch)

The DUAL V trial, sponsored by Novo Nordisk, compares the efficacy and safety of insulin degludec/liraglutide (IDegLira) against insulin glargine in patients with type 2 diabetes mellitus. With a global enrollment of 557 participants across 75 sites in 10 countries, the trial's completion in November 2014 positions IDegLira as a competitive option in the basal insulin market, particularly against established therapies like insulin glargine. The integration of GLP-1 receptor agonism with basal insulin may enhance patient adherence and outcomes, potentially capturing a significant share of the diabetes treatment market. The results may influence prescribing patterns and reimbursement strategies, particularly in markets with high diabetes prevalence.

Matched by conditions: Diabetes Mellitus, Type 2

Comparison of Canagliflozin vs. Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Patients With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease

The clinical trial, sponsored by Janssen Research & Development, LLC, aimed to compare the effects of Canagliflozin against alternative antihyperglycemic treatments on the risk of heart failure hospitalization and lower extremity amputation in patients with Type 2 Diabetes Mellitus (T2DM), particularly those with established cardiovascular disease (CVD). Given the increasing prevalence of T2DM and associated cardiovascular complications, this study addresses a significant market need. Canagliflozin, as an SGLT2 inhibitor, is positioned in a competitive landscape alongside other SGLT2 inhibitors like Empagliflozin and Dapagliflozin, as well as DPP-4 inhibitors and GLP-1 agonists. The outcomes of this study could influence prescribing patterns and market share dynamics in the antihyperglycemic segment, particularly for patients at high risk for heart failure and amputation. The completion of this study may also enhance the clinical profile of Canagliflozin, potentially leading to expanded indications and improved market access.

A Randomized Controlled, Open-label, Multi-center Study With 16-week Beinaglutide or Dulaglutide Assessing Effects on Glucose Control and Weight Loss in Type 2 Diabetes With Overweight or Obesity.

The clinical trial is evaluating Beinaglutide, a novel GLP-1 receptor agonist, against Dulaglutide, an established competitor in the treatment of Type 2 diabetes in overweight or obese patients. Given the rising prevalence of diabetes and obesity, particularly in China, this trial addresses a significant market need. If successful, Beinaglutide could capture market share from Dulaglutide, which is already well-established. The trial's multi-center design and recruitment of 120 participants across four sites enhance its credibility and potential for robust data. The outcomes may influence prescribing practices and market dynamics in the GLP-1 agonist segment, which is experiencing increasing competition. Companies should monitor the trial's progress closely for potential partnership or acquisition opportunities.

Matched by conditions: Diabetes Mellitus, Type 2

A Double-Blind, Randomized, Parallel Group Comparison of the Effects of FX006 and TCA IR (Triamcinolone Acetonide Suspension) on Blood Glucose in Patients With Osteoarthritis of the Knee and Type 2 Diabetes Mellitus

FX006, developed by Pacira Pharmaceuticals, aims to provide a safer alternative to traditional corticosteroids for patients with osteoarthritis of the knee and type 2 diabetes mellitus. The market for osteoarthritis treatments is significant, with increasing demand for effective pain management solutions. The results from this trial suggest FX006 may have a favorable safety profile regarding blood glucose levels compared to immediate-release triamcinolone acetonide (TCA IR), potentially positioning it as a competitive option in the market. Diligence should focus on the regulatory pathway and potential market access strategies, as well as the competitive landscape, particularly against established corticosteroid therapies.

Matched by conditions: Type 2 Diabetes Mellitus

Evaluation of a Pragmatic NT-ProBNP-based Heart Failure Screening Strategy Among Patients With Type 2 Diabetes: STRONG-DM Study (Screening and Treatment Using Risk-based apprOach With NT-ProBNP Guidance in Diabetes Mellitus

The STRONG-DM study, sponsored by the University of Texas Southwestern Medical Center, aims to evaluate a pragmatic heart failure screening strategy utilizing NT-proBNP and clinical risk scores among patients with Type 2 Diabetes. This study is particularly relevant given the increasing prevalence of diabetes and associated cardiovascular complications, representing a significant market opportunity for preventive therapies such as SGLT2 inhibitors and GLP-1 agonists. The collaboration with Roche Diagnostics indicates potential for leveraging diagnostic capabilities, which could enhance the commercial viability of the intervention. The outcomes may influence clinical guidelines and reimbursement strategies, impacting market dynamics for heart failure management in diabetic patients.

A Randomized, Parallel Group, Open-Label, Active-Controlled Study Comparing Acarbose With Voglibose in Patients Who Are Inadequately Controlled With Insulin Glargine Alone or in Combination With Metformin Based on Glycemic Control

This study compares the efficacy and safety of acarbose against voglibose in patients with type 2 diabetes inadequately controlled by insulin glargine and/or metformin. Given the increasing prevalence of type 2 diabetes globally, the potential market for effective oral hypoglycemic agents remains substantial. Bayer's positioning with acarbose could enhance its portfolio in diabetes management, particularly in markets where voglibose is a competitor. The results may influence prescribing patterns and market share dynamics, especially in regions where both drugs are available. Diligence should focus on the competitive landscape, particularly the acceptance of acarbose in clinical practice compared to voglibose and other newer agents.

Matched by conditions: Diabetes Mellitus, Type 2

Pharmacokinetic Drug Interaction Study of Dapagliflozin and Valsartan or Simvastatin in Healthy Subjects

The trial investigates the pharmacokinetic interactions between dapagliflozin, an SGLT2 inhibitor, and two widely used cardiovascular medications, valsartan (an angiotensin receptor blocker) and simvastatin (a statin). Given the increasing prevalence of Type 2 Diabetes Mellitus and cardiovascular diseases, understanding these interactions is critical for optimizing combination therapies. The results may enhance AstraZeneca's positioning in the diabetes and cardiovascular markets, potentially leading to expanded indications for dapagliflozin. Additionally, the collaboration with Bristol-Myers Squibb may strengthen AstraZeneca's portfolio in this therapeutic area. The competitive landscape includes other SGLT2 inhibitors and combination therapies, necessitating a thorough analysis of the trial outcomes to inform strategic decisions.

Matched by conditions: Type 2 Diabetes Mellitus